Compare · SBBP vs TRIL
SBBP vs TRIL
Side-by-side comparison of Strongbridge Biopharma plc (SBBP) and Trillium Therapeutics Inc. (TRIL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SBBP and TRIL operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- TRIL is the larger of the two at $1.94B, about 14.2x SBBP ($136.0M).
- TRIL has more recent analyst coverage (5 ratings vs 0 for SBBP).
- Company
- Strongbridge Biopharma plc
- Trillium Therapeutics Inc.
- Price
- $2.00+1.78%
- $19.30-3.45%
- Market cap
- $136.0M
- $1.94B
- 1M return
- -
- -3.79%
- 1Y return
- -
- -5.02%
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- n/a
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 5
Strongbridge Biopharma plc
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs in the United States. The company offers Keveyis, an oral carbonic anhydrase inhibitor to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. Its clinical-stage product candidates include Recorlev, a cortisol synthesis inhibitor, which is in Phase III clinical trials for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that has completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Trillium Therapeutics Inc.
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Latest SBBP
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares
- SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)
- SEC Form 15-12B filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form EFFECT filed by Strongbridge Biopharma plc
- SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Cohen Fredric J. returned 160,408 units of Ordinary Shares to the company, decreasing direct ownership by 50% to 160,408 units
Latest TRIL
- Defiance ETFs Announces Closure of Select Funds
- Defiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global Markets
- Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
- 10 Psychedelics CEOs To Pay Attention To In 2022
- Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors
- SEC Form 15-12B filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form EFFECT filed by Trillium Therapeutics Inc.
- SEC Form 4: Walker Paul Edward returned 5,736,363 shares to the company
- SEC Form 4 filed by Pucci Paolo